Labcorp Holdings Inc. (LH) Stock Analysis
Recovery setup
Healthcare · Diagnostics & Research
Hold if already holding. Not a fresh buy at $264.76, but acceptable to hold if already in. Reasons: Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%).
Labcorp Holdings provides diagnostic laboratory testing and biopharma drug development services globally through Dx (routine and specialty testing) and BLS (clinical trial support) segments. The company generated $13,951.7 million in 2025 revenues with nearly 71,000 employees... Read more
Hold if already holding. Not a fresh buy at $264.76, but acceptable to hold if already in. Reasons: Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%). Chart setup: Death cross but MACD improving, RSI 59. Mixed signals. Hold existing position. Score 5.6/10, moderate confidence.
Passes 7/10 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 37d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: moderate.
About Labcorp Holdings Inc.
About Labcorp Holdings Inc.
Labcorp Holdings generated $13,951.7 million in 2025 revenues through the Dx segment ($10,876.5 million, 78%) covering routine and specialty testing across more than 2,200 U.S. patient service centers, and the BLS segment ($3,098.2 million, 22%) supporting drug development globally. Nearly 71,000 employees served clients in about 100 countries, and BLS supported 85% of new FDA-approved drugs in 2025.
Dx earns fee-for-service revenue billed to four payer groups: MCOs and third parties (37% of total 2025 revenues), physician and hospital clients (23%), patients (10%), and Medicare/Medicaid (8%). MCO payments are predominantly fee-for-service with a smaller portion under per-member, per-month capitation arrangements. BLS earns fees from pharmaceutical and biotechnology companies for early development research, central laboratory services for clinical trials, and drug approval-related testing; about 59% of BLS revenues originate outside the U.S. The company also offers more than 100 health and wellness tests through its Labcorp OnDemand consumer channel. Since January 1, 2021, the company has invested approximately $3.8 billion in strategic acquisitions, including a 2025 minority stake in SYNLAB for European specialty diagnostics. Nearly all Dx revenue originates in the U.S., while BLS maintains a global central laboratory network with nine ISO 15189-certified locations.
Show full overview
Medicare reimbursement for clinical laboratory testing follows a government-set schedule under PAMA. Rate reductions imposed from 2018 to 2020 cut reimbursement by approximately $245.0 million. Under the Consolidated Appropriations Act signed February 3, 2026, rate changes are frozen for 2026 but phased reductions will resume from 2027 through 2029 capped at 15% per year, with benchmark rates set from CMS's 2025 data collection window. Given Dx accounts for 78% of Labcorp's revenues, PAMA-driven compression on core clinical test reimbursement subjects the majority of the company's revenue base to government-mandated price controls through 2029.
See also: Healthcare · Diagnostics & Research
From Labcorp Holdings Inc.'s most recent 10-K filing, extracted June 11, 2026.
Recent developments
updated 2026-06-17Recent Developments — Labcorp Holdings Inc.
Latest news
- NEWS What To Expect From Labcorp’s (LH) Q1 Earnings - StockStory — StockStory neutral
- NEWS LH (Labcorp Holdings Inc.) delivers 7.2% YoY Q4 2025 revenue growth and small EPS beat, shares edge down 0.8%. - Expert — Cổng thông tin điện tử tỉnh Tây Ninh positive
- NEWS All you need to know about Labcorp (LH) rating upgrade to buy - MSN — MSN positive
- NEWS Evercore ISI Group Raises Labcorp Holdings (LH) Price Target to $300 | LH Stock News - GuruFocus — GuruFocus positive
- NEWS Raleigh Capital Management Inc. Sells 11,248 Shares of Labcorp Holdings Inc. $LH - MarketBeat — MarketBeat neutral
Generated 2026-06-17T09:02:27Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductDx segment78%10-K Item 1: 'Total Dx revenues ... 78'
- MEDIUMCustomerThird party37%10-K Item 1: 'Third party ... 37'
- HIGHGeographicNorth America87%10-K Item 1: 'North America ... 87'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $264.76, but acceptable to hold if already in. Reasons: Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%). Chart setup: Death cross but MACD improving, RSI 59. Mixed signals. Hold existing position. Target $279.11 (+5.4%), stop $252.66 (−4.8%), A.R:R 1.0:1. Score 5.6/10, moderate confidence.
Take-profit target: $279.11 (+5.4% upside). Target $279.11 (+5.4%), stop $252.66 (−4.8%), A.R:R 1.0:1. Stop-loss: $252.66.
Concentration risk — Product: Dx segment (78.0%); Concentration risk — Geographic: North America (87.0%); Thin upside margin: 5.4%.
Labcorp Holdings Inc. trades at a P/E of 23.5 (forward 13.6). TrendMatrix value score: 6.8/10. Verdict: Hold.
28 analysts cover LH with a consensus score of 4.1/5. Average price target: $310.
What does Labcorp Holdings Inc. do?Labcorp Holdings provides diagnostic laboratory testing and biopharma drug development services globally through Dx...
Labcorp Holdings provides diagnostic laboratory testing and biopharma drug development services globally through Dx (routine and specialty testing) and BLS (clinical trial support) segments. The company generated $13,951.7 million in 2025 revenues with nearly 71,000 employees serving clients in approximately 100 countries, with Dx accounting for 78% and BLS 22% of revenues.